Cetrelimab 480 mg

DRUG2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Castration-Resistant Prostatic NeoplasmsProstatic Neoplasms, Castration-Resistant

Phase 1

A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

CompletedNCT03551782

Janssen Research & Development, LLCCastration-Resistant Prostatic Neoplasms

Start: 2018-06-28End: 2021-11-11Updated: 2022-02-25

Phase 2

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Active, not recruitingNCT03431350

Janssen Research & Development, LLCProstatic Neoplasms, Castration-Resistant

Start: 2018-03-02End: 2026-12-31Updated: 2026-03-25

Related Papers

Population Pharmacokinetics of Niraparib/Abiraterone Acetate Administered as Single-Agent Combination and Dual-Acting Tablets Plus Prednisone for Metastatic Castration-Resistant Prostate Cancer.

2025-02-28

MP27-17 NIRAPARIB WITH ABIRATERONE ACETATE AND PREDNISONE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM THE PHASE 2 QUEST STUDY

The Journal of Urology2022-04-072 citations

A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350).

Journal of Clinical Oncology2019-05-204 citations